Cargando…

Prognostic bioindicators in severe COVID-19 patients

BACKGROUND: Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergantini, L., Bargagli, E., d'Alessandro, M., Refini, R.M., Cameli, P., Galasso, L., Scapellato, C., Montagnani, F., Scolletta, S., Franchi, F., Valente, S., Bennett, D., Sebastiani, G., Frediani, B., Dotta, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843114/
https://www.ncbi.nlm.nih.gov/pubmed/33548798
http://dx.doi.org/10.1016/j.cyto.2021.155455
_version_ 1783644079619309568
author Bergantini, L.
Bargagli, E.
d'Alessandro, M.
Refini, R.M.
Cameli, P.
Galasso, L.
Scapellato, C.
Montagnani, F.
Scolletta, S.
Franchi, F.
Valente, S.
Bennett, D.
Sebastiani, G.
Frediani, B.
Dotta, F.
author_facet Bergantini, L.
Bargagli, E.
d'Alessandro, M.
Refini, R.M.
Cameli, P.
Galasso, L.
Scapellato, C.
Montagnani, F.
Scolletta, S.
Franchi, F.
Valente, S.
Bennett, D.
Sebastiani, G.
Frediani, B.
Dotta, F.
author_sort Bergantini, L.
collection PubMed
description BACKGROUND: Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity. MATERIALS AND METHODS: Serum samples were obtained from 24 COVID-19 patients on admission to hospital, before any treatment or infusion of intravenous steroids or invasive ventilation. KL-6 IL-6 and C-peptide were measured by chemiluminescent enzyme immunoassay. IL-6 assay was validated for accuracy and precision. The validity of variables used to distinguish severe from mild-to-moderate patients was assessed by areas under curves (AUC) of the receiver operating characteristic (ROC) and logistic regression was performed to combine parameters of the two groups. RESULTS: In the severe group, IL-6, CRP and KL-6 concentrations were significantly higher than in mild-to-moderate patients. KL-6, IL-6 and CRP concentrations were directly correlated with each other. ROC curve analysis of the logistic regression model including IL-6, KL-6 and CRP showed the best performance with an AUC of 0.95. CONCLUSIONS: Besides corroborating previous reports of over-expression of IL-6 in severe COVID-19 patients requiring mechanical ventilation, analytical determination of other mediators showed that IL-6 concentrations were correlated with those of KL-6 and CRP. The combination of these three prognostic bioindicators made it possible to distinguish severe COVID-19 patients with poor prognosis from mild-to-moderate patients.
format Online
Article
Text
id pubmed-7843114
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78431142021-01-29 Prognostic bioindicators in severe COVID-19 patients Bergantini, L. Bargagli, E. d'Alessandro, M. Refini, R.M. Cameli, P. Galasso, L. Scapellato, C. Montagnani, F. Scolletta, S. Franchi, F. Valente, S. Bennett, D. Sebastiani, G. Frediani, B. Dotta, F. Cytokine Article BACKGROUND: Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers to phenotype patients and to define the role of immuno-inflammatory mediators as biomarkers of severity. MATERIALS AND METHODS: Serum samples were obtained from 24 COVID-19 patients on admission to hospital, before any treatment or infusion of intravenous steroids or invasive ventilation. KL-6 IL-6 and C-peptide were measured by chemiluminescent enzyme immunoassay. IL-6 assay was validated for accuracy and precision. The validity of variables used to distinguish severe from mild-to-moderate patients was assessed by areas under curves (AUC) of the receiver operating characteristic (ROC) and logistic regression was performed to combine parameters of the two groups. RESULTS: In the severe group, IL-6, CRP and KL-6 concentrations were significantly higher than in mild-to-moderate patients. KL-6, IL-6 and CRP concentrations were directly correlated with each other. ROC curve analysis of the logistic regression model including IL-6, KL-6 and CRP showed the best performance with an AUC of 0.95. CONCLUSIONS: Besides corroborating previous reports of over-expression of IL-6 in severe COVID-19 patients requiring mechanical ventilation, analytical determination of other mediators showed that IL-6 concentrations were correlated with those of KL-6 and CRP. The combination of these three prognostic bioindicators made it possible to distinguish severe COVID-19 patients with poor prognosis from mild-to-moderate patients. Elsevier Ltd. 2021-05 2021-01-28 /pmc/articles/PMC7843114/ /pubmed/33548798 http://dx.doi.org/10.1016/j.cyto.2021.155455 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bergantini, L.
Bargagli, E.
d'Alessandro, M.
Refini, R.M.
Cameli, P.
Galasso, L.
Scapellato, C.
Montagnani, F.
Scolletta, S.
Franchi, F.
Valente, S.
Bennett, D.
Sebastiani, G.
Frediani, B.
Dotta, F.
Prognostic bioindicators in severe COVID-19 patients
title Prognostic bioindicators in severe COVID-19 patients
title_full Prognostic bioindicators in severe COVID-19 patients
title_fullStr Prognostic bioindicators in severe COVID-19 patients
title_full_unstemmed Prognostic bioindicators in severe COVID-19 patients
title_short Prognostic bioindicators in severe COVID-19 patients
title_sort prognostic bioindicators in severe covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843114/
https://www.ncbi.nlm.nih.gov/pubmed/33548798
http://dx.doi.org/10.1016/j.cyto.2021.155455
work_keys_str_mv AT bergantinil prognosticbioindicatorsinseverecovid19patients
AT bargaglie prognosticbioindicatorsinseverecovid19patients
AT dalessandrom prognosticbioindicatorsinseverecovid19patients
AT refinirm prognosticbioindicatorsinseverecovid19patients
AT camelip prognosticbioindicatorsinseverecovid19patients
AT galassol prognosticbioindicatorsinseverecovid19patients
AT scapellatoc prognosticbioindicatorsinseverecovid19patients
AT montagnanif prognosticbioindicatorsinseverecovid19patients
AT scollettas prognosticbioindicatorsinseverecovid19patients
AT franchif prognosticbioindicatorsinseverecovid19patients
AT valentes prognosticbioindicatorsinseverecovid19patients
AT bennettd prognosticbioindicatorsinseverecovid19patients
AT sebastianig prognosticbioindicatorsinseverecovid19patients
AT fredianib prognosticbioindicatorsinseverecovid19patients
AT dottaf prognosticbioindicatorsinseverecovid19patients